Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03089554 · ClinicalTrials.gov registry record · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
A Phase 2 study of Cancer, sponsored by Rachel Miller.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 1
- Study location
NCT03089554: Recruiting Phase 2 study of Cancer, sponsored by Rachel Miller.
NCT03089554 is a Phase 2 study of Cancer that is actively recruiting participants, run by Rachel Miller. The registered enrollment target is 93 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03089554, a Phase 2 study of Cancer, is actively recruiting participants, sponsored by Rachel Miller.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based on genomic analysis results and recommendation by the Markey Cancer Center Molecular Tumor Board (MCC MTB).
Primary Outcome
Proportion of patients achieving a PFS ratio ≥1.3.
Conditions Studied
Interventions
- DRUG Therapeutic Intervention
Study Locations (1)
Kentucky
- Markey Cancer Center, University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2017-04-11 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
What NCT03089554 shows while recruiting
NCT03089554 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Therapeutic Intervention is the first listed.
NCT03089554 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT03089554 about?
NCT03089554 is a clinical study titled "Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies". This is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based on genomic analysis results and recommendation by the Markey Cancer Ce...
What is the current status of trial NCT03089554?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2017-04-11. Estimated completion is 2026-04.
What conditions does trial NCT03089554 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT03089554?
The interventions under investigation include: Therapeutic Intervention (DRUG).
Who is sponsoring clinical trial NCT03089554?
This trial is sponsored by Rachel Miller, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03089554 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03089554's enrollment target sits among peer trials
93 334th of 615 higher than 282 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- NCT05674175 · 93 participants · Phase 1
Co-administration of CART22-65s and huCART19 for B-ALL
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI